|
Mouse Strain information
|
||||||||||||||||||||||||
| APB ID | 8797 | |||||||||||||||||||||||
| Added | 01/10/2019 | |||||||||||||||||||||||
| Last Edited | 04/10/2019 | |||||||||||||||||||||||
| Strain nomenclature: | B6.129S7-Spp1tm1Rit/Apb | |||||||||||||||||||||||
| Nickname: | Osteopontin null | |||||||||||||||||||||||
|
Genetics
|
||||||||||||||||||||||||
| Strain Types |
Mutant strain
|
|||||||||||||||||||||||
| Genetic Details |
Targeted knockout
|
|||||||||||||||||||||||
| Mode of Inheritance | Recessive | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Mutant Construction Technique | None | |||||||||||||||||||||||
|
Phenotype
|
||||||||||||||||||||||||
| Phenotype Homozygous State | Mortality/aging: N • homozygotes are viable, fertile and overtly normal with no significant differences in lactation, growth development, or organ and tissue histology Decreased osteoclast cell number: • fewer osteoclasts accumulate at the site of an implanted bone disc compared to in similarly treated wild-type mice. Increased osteoclast cell number: • homozygotes exhibit a 3-fold increase in osteoclast number relative to wild-type mice; ovariectomy does not increase the number of osteoclasts significantly • in vitro, several-fold more osteoclasts are generated in co-culture systems with wild-type calvarial osteoblast cells by using spleen cells (3- to 13-fold) or bone marrow cells (~2- to 4-fold) from homozygous mutant mice compared with wild-type mice. Abnormal osteoclast physiology: • in contrast to wild-type mice, homozygotes are resistant to ovariectomy-induced bone resorption despite a comparable reduction in uterine weight (25-30%) • ovariectomized homozygotes exhibit a 12% reduction in trabecular bone volume in the absence of increased bone formation, whereas ovariectomized wild-type mice show a 58% reduction in trabecular bone volume along with a 73% increase in bone formation • bone resorption and osteoclast formation induced by PTH in cultured mouse calvariae are absent in calvariae from homozygous mutant mice Decreased interferon-gamma secretion: • following treatment with polyvinyl pyrrolidone, mice exhibit a 90% reduction in IL12 production compared with in similarly treated wild-type mice • splenocytes from L. monocytogenes infected mice produce less IFN-gamma when restimulated with heat-killed bacteria compared with similarly treated wild-type mice Increased interleukin-10 secretion: • draining lymph node cells from HSV-1-infected mice produce increased IL10 compared with cells from similarly treated wild-type mice. Decreased interleukin-12 secretion: • following treatment with polyvinyl pyrrolidone, mice exhibit a 95% reduction in IL12 production compared with in similarly treated wild-type mice • draining lymph node cells and splenocytes from HSV-1-infected mice produce decreased IL12 compared with cells from similarly treated wild-type mice. Increased interleukin-4 secretion: • draining lymph node cells from HSV-1-infected mice produce increased IL4 compared with cells from similarly treated wild-type mice. Abnormal inflammatory response: • mice treated with polyvinyl pyrrolidone fail to exhibit a granulomatous response unlike similarly treated wild-type mice Decreased susceptibility to type IV hypersensitivity reaction: • mice infected with HSV-1 do not display a tuberculin-type delayed-type hypersensitivity when challenged with HSV-1 unlike similarly treated wild-type mice Abnormal response to infection: • clearance of Listeria monocytogenes is defective compared to in similarly treated wild-type mice • splenocytes from L. monocytogenes infected mice produce less IFN-gamma when restimulated with heat-killed bacteria compared with similarly treated wild-type mice Decreased susceptibility to viral infection: • mice infected with HSV-1 do not display a tuberculin-type delayed-type hypersensitivity when challenged with HSV-1 unlike similarly treated wild-type mice • corneal HSV-1 infection fails to trigger herpes simplex keratitis unlike in similarly treated wild-type mice | |||||||||||||||||||||||
| Phenotype Heterozygous State | Normal | |||||||||||||||||||||||
| Original Genetic Background | 129S7/SvEvBrd | |||||||||||||||||||||||
| Genetic Background Currently Maintained | C57BL/6 | |||||||||||||||||||||||
|
Strain identification
|
||||||||||||||||||||||||
| How is this strain characterised? |
Genotyping
|
|||||||||||||||||||||||
|
Fertility and Strain maintenance
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
Relevant bibliographic / database references
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
General information
|
||||||||||||||||||||||||
| Associated IP rights? | Unknown | |||||||||||||||||||||||
| Does it Model a Human Condition? | Unknown | |||||||||||||||||||||||
| Applicable Research Areas |
Bone
|
|||||||||||||||||||||||
| Is the strain available in any form to other researchers | Yes | |||||||||||||||||||||||
| APB stock stored as: |
Cryopreserved sperm (from 3 mice)
|
|||||||||||||||||||||||
| Are live mice available? | Unknown | |||||||||||||||||||||||
| MTA needs to be signed? | Yes | |||||||||||||||||||||||
